Epilepsy is a chronic disease in which patient’s brain activities become abnormal due to seizures. Seizure is an unexpected rush of electrical activity in the brain. Seizure is categorized by two types – generalized seizures and focal or partial seizures. Generalized seizures affect the whole brain whereas focal or partial seizures affect just one part of the brain. Global epilepsy drugs market is expected to cross US$ 9 Billion landmark by 2025.
Epilepsy can develop in both males and females of all races, ethnic backgrounds and ages. It affects around 65 Million people globally. United States has around 3.4 Million epilepsy patients; among them around 470 Thousands are children. Epilepsy prevalence varies across various parts of the world. At present, nearly one-third of the total patients are suffering from uncontrollable seizures and are not able to get treatment because no available treatment works for them.
Request a free sample copy of the report: https://www.renub.com/contactus.php
The factors that are driving the global Epilepsy drug market are increasing epilepsy prevalence, growing patient awareness programs, government funding and drugs reimbursement options in European & American countries. Recently, anti-epilepsy drugs Epidiolex approvals for pediatric epilepsies, namely Lennox-Gastaut syndrome and Dravet syndrome in United States will also help in the growth of Epilepsy drug market during the forecast period as well.
Renub Research report titled “Epilepsy Drugs Market by Country (United States, United Kingdom, France, Germany, Italy, Spain, India, China, Japan), Drugs [(Vimpat (Lacosamide), Keppra (Levetiracetam), Sabril (Vigabatrin), Onfi (Clobazam), Fycompa, Briviact (Brivaracetam), Epidiolex, Cenobamate (YKP3089)], Treatment Drugs Generation (First, Second, Third), Company (Eisai Co., Ltd, UCB Inc., H. Lundbeck A/S, GW Pharmaceuticals Plc.) & Forecast” provides a complete analysis of Global Epilepsy Drugs Market. This report also covers all-encompassing analysis of the key growth drivers and challenges, market trends, key players and their projections for the future.
By Country – United States is Dominating Global Epilepsy Drugs Market
The report studies the market of the following countries: United States, United Kingdom, France, Germany, Italy, Spain, India, China and Japan. United States is dominating global epilepsy drugs market. Its share is expected to grow in the years to come due to better healthcare support system, growing awareness and increasing per capita healthcare expenditure.
By Drugs – Vimpat (Lacosamide), Keppra (Levetiracetam) and Epidiolex are playing a significant role
The report studies the market of the following drugs: Vimpat (Lacosamide), Keppra (Levetiracetam), Sabril (Vigabatrin), Onfi (Clobazam), Fycompa, Briviact (Brivaracetam), Epidiolex, Cenobamate (YKP3089). At present, Vimpat (Lacosamide) and Keppra (Levetiracetam) are playing the significant role for the epilepsy treatment. Epidiolex has a bright future ahead.
By Drugs Category – Second and Third Generation Plays the Significant Role
In this report, we have categorized the epilepsy drugs market into three generation; First Generation, Second Generation, Third Generation. It is anticipated that second and third generation plays the significant role in the global epilepsy drugs market during the forecast period of 2019-2025.
Access full Research: https://www.renub.com/epilepsy-drugs-market-p.php
Eisai Co., Ltd, UCB Inc., H. Lundbeck A/S and GW Pharmaceuticals Plc. are some of the top companies that deal efficiently in epilepsy business globally. These companies have been studied thoroughly in the report.
Countries covered in this report are:
• United States
• United Kingdom
Epilepsy Drugs Category – By Generation
• First Generation
• Second Generation
• Third Generation
Drugs covered in this report are:
• Vimpat (Lacosamide)
• Keppra (Levetiracetam)
• Sabril (Vigabatrin)
• Onfi (Clobazam)
• Briviact (Brivaracetam)
• Cenobamate (YKP3089)
Companies covered in this report are:
• Eisai Co., Ltd
• UCB Inc.
• H. Lundbeck A/S
• GW Pharmaceuticals Plc.
If the information you seek is not included in the current scope of the study kindly share your specific requirements with our custom research team at firstname.lastname@example.org
Browse Related Reports :
Key Topics Covered :
1.1 Market Definition
1.2 Currency Conversion
2. Research Methodology
3. Executive Summary
4. Global Epilepsy Drugs Market (2013 – 2025)
5. Market Share – Global Epilepsy Drugs (2013 – 2025)
5.1 By Country
5.2 By Drugs Category
5.3 By Drugs
6. Country – Global Epilepsy Drugs Market Analysis (2013 – 2025)
6.1 United States
6.2 United Kingdom
7. By Drugs Category – Global Epilepsy Drugs Market Analysis (2013 – 2025)
7.1 First Generation
7.2 Second Generation
7.3 Third Generation
8. By Drugs – Global Epilepsy Drugs Market Analysis (2013 – 2025)
8.1 Vimpat (Lacosamide)
8.2 Keppra (Levetiracetam)
8.3 Sabril (Vigabatrin)
8.4 Onfi (Clobazam)
8.6 Briviact (Brivaracetam)
8.8 Cenobamate (YKP3089)
9. Growth Drivers
9.1 Growing Awareness Programs Worldwide
9.2 Presence of Promising Pipeline for Epilepsy Therapeutics
10.1 New Restrictions on Epilepsy Drug
10.2 High Cost of Antiepileptic Drugs
11. Eisai Co., Ltd.
11.1 Company Overview
11.3 Financial Insight
12. UCB Inc.
12.1 Company Overview
12.3 Financial Insight
13. H. Lundbeck A/S
13.1 Company Overview
13.3 Financial Insight
14. GW Pharmaceuticals Plc.
14.1 Company Overview
14.3 Financial Insight
Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide wide range of business research solutions that helps companies in making better business decisions. Our clients rely on our market analysis and data to make informed knowledgeable decisions. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.
Company Name: Renub Research
Contact Person: Rajat Gupta
Email: Send Email
Address:225 Kristie Ln
Country: United States